Theravance Biopharma TBPH Return on equity

Return on equity at other companies

Gyre Therapeutics, Inc.GYRE

-16%-18.3pp

Rigel PharmaceuticalsRIGL

174.1%—

LQD

Liquidia CorporationLQDA

-181%+57.4pp

Royalty PharmaRPRX

8.5%-2.2pp

United TherapeuticsUTHR

19.3%0.0pp

Zevra Therapeutics, Inc.ZVRA

34.8%+31.3pp

FAQ

What is Theravance Biopharma's return on equity?

Theravance Biopharma (TBPH) reported return on equity of 50.2% in Q1 2026.

How has Theravance Biopharma's return on equity changed year-over-year?

Theravance Biopharma's return on equity increased by 259.5% year-over-year, from -31.5% to 50.2%.

What is the long-term trend for Theravance Biopharma's return on equity?

Over 2 years (2023 to 2025), Theravance Biopharma's return on equity has grown at a 63.1% compound annual growth rate (CAGR), from -16.9% to 44.8%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.